Ting Shi

32 West 7th Avenue
Tianjin, 300308, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Deep molecular remission and encouraging survival without transplantation: V-CAG for arsenic-resistant relapsed APL.

Deep molecular remission and encouraging survival without transplantation: V-CAG for arsenic-resistant relapsed APL.

Journal: British journal of haematology

Published: June 14, 2026

Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting.

Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting.

Journal: Experimental hematology & oncology

Published: May 08, 2026

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine.

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine.

Journal: Blood cancer journal

Published: March 30, 2026

Ultra-rapid and high-titer biomanufacturing of trehalose 6-phosphate by an in vitro synthetic biology platform.

Ultra-rapid and high-titer biomanufacturing of trehalose 6-phosphate by an in vitro synthetic biology platform.

Journal: Bioresources and bioprocessing

Published: January 11, 2026

Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report.

Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report.

Journal: Annals of hematology

Published: September 25, 2025

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial.

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial.

Journal: Blood cancer journal

Published: June 30, 2025

Complete biotransformation of cellulose to starch in vitro.

Complete biotransformation of cellulose to starch in vitro.

Journal: National science review

Published: May 27, 2025

Biosynthesis of a healthy natural sugar D-tagatose: advances and opportunities.

Biosynthesis of a healthy natural sugar D-tagatose: advances and opportunities.

Journal: Critical reviews in biotechnology

Published: April 23, 2025

First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid.

First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 28, 2024

Acute promyelocytic leukemia with TTMV::RARA fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment.

Acute promyelocytic leukemia with TTMV::RARA fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment.

Journal: Haematologica

Published: April 18, 2024

Personalized therapy guided by single-cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report.

Personalized therapy guided by single-cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report.

Journal: British journal of haematology

Published: February 11, 2024

Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting.

Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting.

Journal: Journal of hematology & oncology

Published: February 06, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026